Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

Umeclidinium-vilanterol is associated with improved clinical outcomes in symptomatic patients with chronic obstructive pulmonary disease.

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Most people with asthma can be effectively managed with an inhaled corticosteroid (ICS), alone or in combination with a long-acting β2-agonist (LABA). However, a significant number of patients with ...

Hanmi Pharmaceutical signed an agreement last Tuesday with Boehringer Ingelheim Korea to distribute and promote three chronic obstructive pulmonary disease (COPD) treatments nationwide: Spiriva ...

Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of tiotropium dry powder inhaler, 18 mcg/capsule, in the Chinese market, for the treatment ...

Lupin Ltd announces a deal with China's Sino Universal Pharmaceuticals to commercialize its Tiotropium dry powder inhaler in China, targeting COPD treatment. Under the agreement, Sino Universal will ...

Boehringer Ingelheim’s new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company’s inhalers is now available. Boehringer's first-of-its-kind program automatically ...